Key Highlights: The FDA approved marketing of aducanumab for the treatment of Alzheimer’s disease under a special accelerated approval process. Aducanumab has not yet been proven to slow the progression […]

The Lewy Body Dementia Association is interested in establishing a Research Mentorship Program. The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced […]

The Lewy Body Dementia Association is deeply concerned about the recent ruling by the FDA in which it rejected ACADIA Pharmaceutical’s supplemental new drug application for pimavanserin for the treatment […]

LBDA’s Research Centers of Excellence (RCOE) program presented a virtual symposium on “biomarkers” on January 25, 2021.  A biomarker is a biological sign that reveals the presence or severity of […]

Study locates five genes that may play a critical role in Lewy body dementia. Source: National Institutes of Health In a study led by National Institutes of Health researchers, scientists […]

The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]

What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]

Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD).  To address this issue, LBDA is proud to […]

In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]

Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]